Business
Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin
Montreal, Quebec--(Newsfile Corp. - September 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to share the interview of Dr. Amie Phinney, Defence's director, strategy & business advisor, with Ellis Martin on Money Talk Radio.To listen to the interview, please visit:https://youtu.be/HhhfU2exrqwWhat you'll learn in this interview:How Dr. Phinney's career...
About this update from Defence Therapeutics Inc Class A
[{"type":"text","content":"Montreal, Quebec--(Newsfile Corp. - September 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to share the interview of Dr. Amie Phinney, Defence's director, strategy & business advisor, with Ellis Martin on Money Talk Radio.","length":396,"tagName":"p"},{"id":"HhhfU2exrqw","subtype":"videoIframe","type":"youtube","url":"https://www.youtube.com/embed/HhhfU2exrqw","width":560,"height":315,"anchorId":"68acb72a-2809-5b99-bb40-39b80e8056e4"},{"type":"text","content":"To listen to the interview, please visit:https://youtu.be/HhhfU2exrqw","length":70,"tagName":"p","attribs":{}},{"type":"text","content":"What you'll learn in this interview:","length":40,"tagName":"p"},{"type":"text","content":"How Dr. Phinney's career path from the University of Guelph to the University of Basel, and into global pharma leadership, shaped her unique perspective on the intersection of science and business.","length":201,"tagName":"p"},{"type":"text","content":"Why Accum® is a game-changer for ADC delivery, giving drugs "laser-guided precision" inside cancer cells, improving payload efficiency, and reducing toxic side effects.","length":178,"tagName":"p"},{"type":"text","content":"The analogy: instead of sending 100 soldiers to target a cancer cell with only 2 reaching the nucleus, Accum® allows 10 to go in with 2 succeeding—achieving the same effect with far less collateral toxicity.","length":207,"tagName":"p"},{"type":"text","content":"Why ADCs, though powerful, are often relegated to second-line therapy due to dose-limiting toxicity—and how Accum® may enable their use as first-line therapies.","length":160,"tagName":"p"},{"type":"text","content":"Defence's strategy to protect its strong IP portfolio worldwide, including a "picket fence" approach covering multiple aspects of the delivery platform.","length":166,"tagName":"p"},{"type":"text","content":"Near-term revenue outlook: how Defence plans to partner with existing ADC developers, manufacture Accum®, and expand its applications to novel therapies.","length":153,"tagName":"p"},{"type":"text","content":"Why this matters:","length":17,"tagName":"p"},{"type":"text","content":"Antibody-drug conjugates a...